Skip to main content

Table 2 Summary for the extrachromosomal circular DNA-linked drug resistance

From: Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance

Genes Drugs Function Cancers Refs
DHFR MTX Elimination of DHFR on DMs increases MTX sensitivity Colon cancer [36]
DHFR MTX Elimination of DHFR on DMs increases MTX sensitivity Colon cancer [38]
DHFR MTX Amplification of DM-form DHFR promotes MTX resistance Cervical cancer [39]
DHFR MTX X-ray induces MTX resistance due to DM-form amplified DHFR Breast Cancer [121]
EGFRvIII Erlotinib Reducing EGFRvIII-bearing extrachromosomal DNA resultes in erlotinib resistance Glioblastoma [128]
MDM2 Erlotinib Amplification of DM-form MDM2 promotes erlotinib resistance Glioblastoma [128]
HER2 Trastuzumab Loss of DM-form HER2 has no effect on trastuzumab resistance Breast Cancer [129]
c-Myc HU and retinoic acid Reducing c-Myc-bearing DMs enhances therapeutic sensitivity Leukemia [134]
MYCN HU Elimination of MYCN on DMs increases HU sensitivity Neuroblastoma [135]
c-Myc HU Reducing c-Myc-bearing DMs enhances HU sensitivity Colon cancer (136)
MDR1 HU Loss of DM-form MDR1 promotes HU sensitivity Oral squamous cell carcinoma [137]
CA125 HU Low levels of DM-form CA123 after HU treatment Ovarian cancer [138]